The Chinese medicine industry needs to break the monopoly of research and development of new drugs in Europe and America

With the long-term monopolization of new drug research and development in the world by European and American chemical pharmaceuticals, the development of new drugs is increasingly frustrating. Today, although computer-assisted new technologies, such as high-throughput screening, and modern biotechnology such as genomics and proteomics have been developed, it is necessary to find a brand-new drug that looks like a needle in a haystack. The investment of enterprises is getting bigger and bigger, the efficiency is getting lower and lower, and the gains are getting less and less. Faced with this dilemma, the entire industry can not help asking: where is the Yang Guan Road for new drug development? The component Chinese medicine is a new concept proposed by Yan Xijun, President of the Tasly Group, at the World Congress of Traditional Medicine held in Beijing. It is also a breakthrough in modernization of traditional Chinese medicine that this state-level innovative enterprise has explored after six years of practice.

Yan Xijun said in an interview with reporters that the development of component Chinese medicine is based on the original principle of traditional Chinese medicine, the effective components of traditional Chinese medicine are separated through modern techniques, the synergies of the components are clearly defined, the homogeneity of the active ingredients is ensured, and pharmaceuticals are established. standard. At the same time, the company can also select effective ingredients to form a new drug without any impurities under the guidance of TCM principle of differentiation and treatment, so that its targeted and treatment accuracy is greatly improved.